IOVA IOVANCE BIOTHERAPEUTICS, INC.

8-K Current Report

Filed: February 24, 2026

Health Care

Biological Products, (No Diagnostic Substances)

IOVANCE BIOTHERAPEUTICS, INC. (IOVA) 8-K current report filed with SEC EDGAR on February 24, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
2 items

Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events

AI Filing Analysis
8-K

Item 2.02 · Results of Operations and Financial Condition

• Q1 2025 earnings results disclosed via press release in Exhibit 99.1
• Exhibit filed under Reg FD safe harbor — not subject to Section 18 liability, limiting legal exposure for investors relying on it

+1 more insights

Item 8.01 · Other Events

• Updated corporate presentation filed Feb 24, 2026 — potential signal of new strategic messaging or data to analysts and investors
• Full substance in Exhibit 99.2; investors should review for pipeline updates, commercial metrics, or guidance changes

Get deeper insights on IOVANCE BIOTHERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.